Your browser doesn't support javascript.
loading
Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer.
Rigakos, Georgios; Razis, Evangelia; Koliou, Georgia-Angeliki; Oikonomopoulos, Georgios; Tsolaki, Eleftheria; Sperinde, Jeff; Chrisafi, Sofia; Zarkavelis, George; Pazarli, Elissavet; Batistatou, Anna; Kourea, Helen P; Papakostas, Pavlos; Bafaloukos, Dimitrios; Asimakopoulou, Natalia I; Res, Eleni; Kotsakis, Athanasios; Pectasides, Dimitrios; Koutras, Angelos; Christodoulou, Christos; Fountzilas, George.
Afiliação
  • Rigakos G; Third Department of Medical Oncology, Hygeia Hospital, Athens, Greece; grigakos@oncologists.gr.
  • Razis E; Third Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
  • Koliou GA; Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece.
  • Oikonomopoulos G; Second Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
  • Tsolaki E; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Sperinde J; Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA, U.S.A.
  • Chrisafi S; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Zarkavelis G; Department of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece.
  • Pazarli E; Department of Pathology, Papageorgiou Hospital, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece.
  • Batistatou A; Department of Pathology, Ioannina University Hospital, Ioannina, Greece.
  • Kourea HP; Department of Pathology, University Hospital of Patras, Rion, Greece.
  • Papakostas P; Oncology Unit, Hippokration Hospital, Athens, Greece.
  • Bafaloukos D; First Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
  • Asimakopoulou NI; Third Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
  • Res E; Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
  • Kotsakis A; University Hospital of Heraklion School of Medicine, University of Crete, Heraklion, Greece.
  • Pectasides D; Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece.
  • Koutras A; Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras, Greece.
  • Christodoulou C; Second Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
  • Fountzilas G; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Anticancer Res ; 41(4): 1793-1802, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33813384
BACKGROUND/AIM: Human epidermal growth factor receptor 2 (HER2) P95-isoform could be involved in trastuzumab resistance in HER2 metastatic breast cancer. MATERIALS AND METHODS: A total of 114 metastatic breast cancer patients treated with trastuzumab were evaluated retrospectively. HER2 was centrally reviewed. P95 was evaluated along with other markers possibly affecting trastuzumab efficacy in regards to progression-free survival and overall survival. RESULTS: HER2 was centrally negative in 54 cases. P95 expression was significantly higher in HER2-positive tumors. High p95 was associated with gain of HER2 copy number variations (CNVs), high pHER2Tyr877, Ki67 and HER2 mRNA. P95 as a continuous variable was positively correlated with mRNA expression of HER2 and negatively correlated with HER4 and IGF1. HER2-negative p95-high patients had a marginally higher risk for death (HR=2.15, p=0.055). CONCLUSION: p95 was associated with higher HER2 CNVs and mRNA expression, pHER2Tyr877 expression and high Ki67, indicating a more aggressive phenotype.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Trastuzumab / Antineoplásicos Imunológicos Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Anticancer Res Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Trastuzumab / Antineoplásicos Imunológicos Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Anticancer Res Ano de publicação: 2021 Tipo de documento: Article